What’s Causing Seres Therapeutics Inc (MCRB) Stock’s -50.34% Drop Over the Last Six Months?

JP Morgan has recently reduced Seres Therapeutics Inc (MCRB) stock to Underweight rating, as announced on October 24, 2024, according to Finviz. Earlier, on June 26, 2023, Oppenheimer had resumed the stock to Outperform, setting a price target of $12. JP Morgan also initiated Neutral rating with a price target of $7. Additionally, Goldman reduced Sell rating on July 23, 2021, with a target price of $7. Goldman analysts, in their report published on May 18, 2021, also resumed Neutral rating and set a price target of $24 for Seres Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.

Seres Therapeutics Inc (MCRB) Stock Trading Recap

On Thursday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.74 which represents a decrease of $-0.04 or -5.13% from the prior close of $0.78. The stock opened at $0.75 and touched a low of $0.71 during the day, reaching a high of $0.8. The volume of shares traded was 10.63 million exceeding the average volume of 2.49 million.


Sponsored

MCRB Stock Performance and Moving Averages

In recent trading, Seres Therapeutics Inc (MCRB) stock price has shown some volatility, fluctuating -13.53% over the last five trades and -16.34% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -50.34%, and it has plunged by -9.87% in the previous three months. Currently, MCRB is trading at -15.02%, -10.38%, and -16.96% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.

As of the latest trading close, MCRB, a Healthcare sector stock, is trading -51.96% below its 52-week high but remains 36.11% above its 52-week low. The Average True Range (ATR) (14 days) of 0.07 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.

Seres Therapeutics Inc’s Profitability and Valuation Ratios

Seres Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -225450.00% and a profit margin of -269034.37%, with a gross margin of -50.34%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.

In terms of valuation, Seres Therapeutics Inc’s market capitalization stands at $125.50 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 2091.61, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 5.23, comparing the market value to the company’s book value.

Understanding Insider Trading

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 26.90% of Seres Therapeutics Inc (MCRB)’s shares, while financial institutions hold 23.58%.

Related Posts

Unlock Your Investment Potential: Get Your 100% Free eBook

Best Space Stocks To Buy

A detailed analysis of Three Best Space Stocks to Buy, each selected based on Innovations, Growth Metrics & Achievements

No thanks

Best Space Stocks to Buy!

Unlock Your Investment Potential: Get Your 100% Free eBook

A Detail Analysis of Three Best Space Stocks to Buy, Eash Selected Based on Innovations, Growth Metrics & Achievements